drugset / Trial / NCT06927466
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Phase 1
Recruiting
33 enrolled
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety and tolerability of B019 in subjects.
Timeline
- Start
- 2024-09-19
- Primary completion
- 2026-01-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B019 | Unknown | 1e+06 cells/kg | Intravenous |
| Subject | B019 | Unknown | 1e+07 cells/kg | Intravenous |